Transfusion-associated transmission of West Nile virus, United States 2003 through 2005

TitleTransfusion-associated transmission of West Nile virus, United States 2003 through 2005
Publication TypeJournal Article
Year of Publication2006
AuthorsMontgomery SP, Brown JA, Kuehnert M, Smith TL, Crall N, Lanciotti RS, Macedo de Oliveira A, Boo T, Marfin AA
Pagination2038 - 46
Date PublishedDec
ISSN0041-1132 (Print) 0041-1132 (Linking)
Accession Number17176314
KeywordsAdolescent, Aged, Aged, 80 and over, Blood Donors, Blood Transfusion / *adverse effects, Female, Humans, Male, Middle Aged, Nucleic Acid Amplification Techniques, Time Factors, United States / epidemiology, West Nile Fever / epidemiology / *transmission

BACKGROUND: National blood donation screening for West Nile virus (WNV) started in June 2003, after the documentation of WNV transfusion-associated transmission (TAT) in 2002. STUDY DESIGN AND METHODS: Blood donations were screened with investigational nucleic acid amplification assays in minipool formats. Blood collection agencies (BCAs) reported screening results to state and local public health authorities. Donor test results and demographic information were forwarded to CDC via ArboNET, the national electronic arbovirus surveillance system. State health departments and BCAs also reported suspect WNV TATs to CDC, which investigated these reports to confirm WNV infection in blood transfusion recipients in the absence of likely mosquito exposure. RESULTS: During 2003 to 2005, a total of 1,425 presumptive viremic donors were reported to CDC from 41 states. Of 36 investigations of suspected WNV TAT in 2003, 6 cases were documented. Estimated viremia levels were available for donations implicated in four TAT cases; the median estimated viremia was 0.1 plaque-forming units (PFUs) per mL (range, 0.06-0.50 PFU/mL; 1 PFU equals approximately 400 copies/mL). CONCLUSIONS: National blood screening for WNV identified and removed more than 1,400 potentially infectious blood donations in 2003 through 2005. Despite the success of screening in 2003, some residual WNV TAT risk remained due to donations containing very low levels of virus. Screening algorithms employing selected individual-donation testing were designed to address this residual risk and were fully implemented in 2004 and 2005. Continued vigilance for TAT will evaluate the effectiveness of these strategies.

Notify Library Reference ID1031

Related Incidents